Synaptogenix (NASDAQ:TAOX – Get Free Report) and Shineco (NASDAQ:SISI – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and price targets for Synaptogenix and Shineco, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synaptogenix | 1 | 0 | 0 | 0 | 1.00 |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Synaptogenix and Shineco”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synaptogenix | $300,000.00 | 96.74 | -$28.74 million | ($3.85) | -1.01 |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
Shineco has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Shineco has a beta of -1.61, suggesting that its share price is 261% less volatile than the S&P 500.
Profitability
This table compares Synaptogenix and Shineco’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synaptogenix | -2,153.97% | -128.51% | -97.54% |
| Shineco | -380.55% | -79.89% | -33.01% |
Institutional & Insider Ownership
10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 4.1% of Shineco shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 0.0% of Shineco shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Shineco beats Synaptogenix on 6 of the 11 factors compared between the two stocks.
About Synaptogenix
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
